Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Status:
Completed
Trial end date:
2014-07-24
Target enrollment:
Participant gender:
Summary
Locally advanced or metastatic breast cancer in postmenopausal women with negative Human
Epidermal Growth Factor Receptor 2 (HER2), who are candidates for hormone treatment and who
have not received previous chemotherapy or hormonotherapy for the metastatic disease.